Stealth BioTherapeutics

Executive Summary

Stealth BioTherapeutics is a commercial-stage biopharmaceutical company dedicated to developing therapies for mitochondrial dysfunction, with a particular focus on ultra-rare genetic diseases and age-related conditions. The company gained significant traction with the accelerated FDA approval of its lead asset, elamipretide (Rekambys), for Barth syndrome, an X-linked mitochondrial disorder. This approval validates Stealth's platform and provides a commercial foundation. The company is now advancing a pipeline targeting larger indications, including dry age-related macular degeneration (AMD) and primary mitochondrial myopathy (PMM), which could expand its addressable market substantially. With a differentiated mechanism that targets mitochondrial membranes, Stealth aims to address the root cause of cellular energy deficits in aging and disease. Stealth BioTherapeutics is currently focusing on expanding elamipretide's label and generating pivotal data in additional indications. The company's near-term strategy hinges on advancing its Phase 3 program in dry AMD, a high unmet need area with no approved therapies. Positive outcomes could unlock a multi-billion-dollar market. Additionally, further label expansion into PMM would strengthen its orphan drug portfolio. As a private company, Stealth may consider strategic partnerships or an IPO to fund commercialization and pipeline development. The company's progress in mitochondrial medicine positions it as a pioneer in targeting the fundamentals of cellular health.

Upcoming Catalysts (preview)

• Q4 2026Top-line data from Phase 3 trial of elamipretide in dry AMD40% success
• H1 2027FDA decision on label expansion for primary mitochondrial myopathy (PMM)60% success
• Q3 2026Announcement of ex-U.S. partnership for commercialization of elamipretide70% success